Comprehensive Overview

The Group is an RNA therapy biopharmaceutical company with candidate products in the pre-clinical and clinical stages, focusing on exploring and developing innovative drugs to treat adaptations where there are medical needs and market opportunities. The group initially focused on oncology and fibrillation products, as well as antiviral products and products that target the liver. Currently, it has independently developed and has global rights to the main candidate products STP705 and STP707. Currently, two patents granted and seven pending patent applications in the US cover the group's core product STP705, including two from China and five from the US.

Risk Factors

RNA therapy is viewed as an emerging and relatively novel therapy. The mechanism of action of this treatment has not been fully clarified, and AEs or side effects have been discovered in preclinical studies and clinical trials using such therapy in cancer patients. The Group has spent a large amount of money to promote the development of candidate drugs. If the candidate drug does not express the safety and efficacy that made the supervisory authority satisfied, or if future clinical trials do not produce positive results, and if the candidate drug does not obtain regulatory approval at the time or end due to poor clinical trial results, it is impossible to realize any benefit, which will have a significant adverse effect on the Group's business, financial situation, operating performance and prospects.